CELC | tickerfilter.com

Fundamental analysis

33%

Profitability 25%

Dept financing 1%

Liquidity 50%

Performance 45%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-4.12%

1 Month

12.50%

3 Months

12.07%

6 Months

83.34%

1 Year

1,049.19%

2 Year

584.66%

Key data

Stock price

$126.07

P/E Ratio

N/A

DAY RANGE

$117.56 - $127.18

EPS

-$3.79

52 WEEK RANGE

$9.51 - $127.34

52 WEEK CHANGE

$979.95

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

48.337 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-13-2025

BETA

1.38

PUBLIC FLOAT

AVERAGE 10 VOLUME

$744,330

AVERAGE 30 VOLUME

$747,841

Company detail

CEO: Brian F. Sullivan
Region: US
Website: celcuity.com
Employees: 40
IPO year: 2017

Issue type: Common Stock
Market: XNAS
Industry: Healthcare/Services – Health
Sector: Services

Celcuity Inc. focuses on the development of molecularly targeted therapies for cancer patients in the United States. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3k signaling activity in breast and ovarian tumor cells.

CELC - Celcuity Inc.